Skip to main content

Table 1 Effects of GPR40 agonists on sEPSC frequency

From: Attenuation of inflammatory and neuropathic pain behaviors in mice through activation of free fatty acid receptor GPR40

 

MEDICA16 (10 μM)

GW9508 (30 μM)

 

Increase

Decrease

No change

Increase

Decrease

No change

Control

156.6 ± 25.5 (6/21)

69.3 ± 4.5***(12/21)

104.9 ± 1.2 (3/21)

136.0 ± 15.1 (3/8)

61.7 ± 9.2 (3/8)

101.8 ± 6.5 (2/8)

Carrageenan 6 h

― (0/8)

52.6 ± 10.6** (6/8)

92.9 ± 1.6 (2/8)

― (0/8)

56.0 ± 7.7** (7/8)

109.9 (1/8)

CFA 3d

133.3 ± 12.0 (3/15)

59.1 ± 4.6***(12/15)

― (0/15)

― (0/14)

51.4 ± 6.3***(14/14)

― (0/14)

SNL 2–3 w

113.8 (1/15)

54.4 ± 6.5***(14/15)

― (0/15)

― (0/7)

53.3 ± 9.8** (7/7)

― (0/7)

  1. CFA, complete Freund’s adjuvant, SNL, spinal nerve ligation.
  2. Increase or decrease means the increase or decrease of 10% or more in the sEPSC frequency, respectively.
  3. Values are expressed as mean ± SEM (%) and the proportion of neurons exhibiting increase, decrease or no change in parentheses.
  4. ** P < 0.01, *** P < 0.001, when compared with pretreatment control (Student’s t test).
Back to article page

Molecular Pain

ISSN: 1744-8069

Contact us